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http://dx.doi.org/10.1053/j.gastro.2017.05.011BACKGROUND & AIMS: Statin use has been associated with a
reduced incidence of colorectal cancer and might also affect
survival of patients diagnosed with colon cancer. Statins are
believed to inhibit Ras signaling and may also activate the bone
morphogenetic protein (BMP) signaling pathway in colorectal
cancer cells. We investigated the effects of statins on overall
survival of patients with a diagnosis of colon cancer, and
whether their effects were associated with changes in KRAS or
the BMP signaling pathways. METHODS: Data were derived
from the PHARMO database network (Netherlands) and linked
to patients diagnosed with colon cancer from 2002 through
2007, listed in the Eindhoven Cancer Registry. We obtained
information on causes of death from statistics Netherlands. We
constructed a tissue microarray of 999 colon cancer specimens
from patients who underwent surgical resection from 2002
through 2008. Survival was analyzed with statin user status
after diagnosis as a time-dependent covariate. Multivariable
Poisson regression survival models and Cox analyses were used
to study the effect of statins on survival. Tumor tissues were
analyzed by immunohistochemistry for levels of SMAD4,
BMPR1A, BMPR1B, and BMPR2 proteins. Tumor tissues were
considered to have intact BMP signaling if they contained
SMAD4 plus BMPR1A, BMPR1B, or BMPR2. DNA was isolated
from tumor tissues and analyzed by quantitative polymerase
chain reaction to detect mutations in KRAS. The primary
outcome measures were overall mortality and cancer-specific
mortality. RESULTS: In this cohort, 21.0% of the patients
(210/999) were defined as statin users after diagnosis of colon
cancer. Statin use after diagnosis was significantly associated
with reduced risk of death from any cause (adjusted relative
risk [RR], 0.67; 95% confidence interval [CI], 0.51–0.87;
P ¼ .003) and death from cancer (adjusted RR, 0.66; 95% CI,
0.49–0.89; P ¼ .007). Statin use after diagnosis was associated
with reduced risk of death from any cause or from cancer for
patients whose tumors had intact BMP signaling (adjusted RR,
0.39; 95% CI, 0.22–0.68; P ¼ .001), but not for patients whose
tumors did not have BMP signaling (adjusted RR, 0.81; 95% CI,
0.55–1.21; P ¼ .106; P < .0001 for the interaction). Statin use
after diagnosis was not associated with reduced risk of death
from any cause or from cancer for patients whose tumors did
not contain KRAS mutations (adjusted RR, 0.81; 95% CI,
0.56–1.18; P ¼ .273) or whose tumors did have KRAS muta-
tions (adjusted RR, 0.59; 95% CI 0.35–1.03; P ¼ .062; P ¼ .90
for the interaction). CONCLUSIONS: In an analysis of 999
patients with a diagnosis of colon cancer, we associated statin
with reduced risk of death from any cause or from cancer. Thebenefit of statin use is greater for patients whose tumors have
intact BMP signaling, independent of KRAS mutation status.
Randomized controlled trials are required to confirm these
results.Keywords: Colorectal cancer; Signal Transduction; Patient
Selection; Cholesterol-lowering Drug.
lthough colorectal cancer survival has doubled inAthe last 40 years, 5-year survival remains low at
only 65%.1 Current chemotherapy treatment for colorectal
cancer results in significant toxicity, limiting its use in early
stage disease, in the elderly, and in patients with comorbidity,
so that there is a clear unmet clinical need for new, less toxic
treatment options. Previously, aspirin has been shown to
increase survival when used after diagnosis, thus providing a
potential new minimally toxic adjuvant treatment option for
colorectal cancer.2,3 Statins may represent such a treatment
option as well, either alone or in combination with aspirin.
Aside from their proven efficacy in primary and secondary
prevention of cardiovascular morbidity and mortality,4 sta-
tins have been shown, in several but not all studies, to reduce
the risk of developing colorectal cancer.5 In vitro and in vivo
studies indicate that statins inhibit proliferation and induce
apoptosis in colorectal cancer cells.6,7 However, the exact
molecular mechanism by which statins influence colorectal
cancer remains under debate. Cancer therapy is increasingly
focused on personalized therapy via pharmacologic modu-
lation of specific molecular pathways targeted to sensitive
tumors identified by molecular subtyping; statins could
potentially be more effective in a specific subgroup of
cancers.
There are several potential molecular mechanisms of
action to explain the therapeutic effects of statins in
EDITOR’S NOTES
BACKGROUND AND CONTEXT
The long-term use of statins has been linked to improved
survival after a diagnosis of colorectal cancer but the
mechanism for this protective effect is unclear.
NEW FINDINGS
The researchers show that statin use after a diagnosis of
colorectal cancer is associated with improved cancer
specific survival. This effect was strongest in cancers
with an intact BMP cell signaling pathway and
independent of cancer KRAS mutations.
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This is a retrospectivemolecularpathological epidemiological
study.
IMPACT
BMP pathway analysis of colorectal cancers could help
identify patients that benefit most from statin use.





ATcolorectal cancer. Statins inhibit 3-hydroxy-3-methylglutaryl
coenzyme A (HMG-CoA) reductase; an enzyme that plays an
essential role in mevalonate synthesis. Inhibition of the
mevalonate pathway not only disrupts cholesterol synthesis,
but also farnesyl pyrophosphate synthesis, which is essen-
tial for the prenylation of GTPases like KRAS.8 It is therefore
thought that statins might act on colorectal cancer by
inhibiting KRAS. KRAS mutations are prevalent in 40% of
colorectal cancers and result in constitutively active form of
KRAS.9
Another theory hypothesizes that statins act through
activation of the bone morphogenetic protein signaling
(BMP) pathway. Statins activate the BMP pathway in bone,10
and we have previously shown that they also do this in
colorectal cancer.11 Interestingly, statins are only effective
in colorectal cancer cells where BMP signaling is intact.7
BMP signaling is frequently disrupted in colorectal cancer
through loss of SMAD4, the central component of the
signaling cascade, or reduced BMP receptor expression.12,13
The aim of our study was to evaluate whether statins
might be effective as adjuvant therapy in colon cancer by
correlating post-diagnosis statin use with patient survival in
a cohort in which we have previously observed a survival
benefit with aspirin use after diagnosis. Secondly, we tried
to uncover the molecular background in which statins are
able to execute their tumor-suppressive function, thereby
considering the KRAS mutational status and the BMP
signaling pathway functionality in relation to statin use and
patient survival.Materials and Methods
Retrospective Study Cohort
All patients diagnosed with colon cancer between 2002 and
2007 were selected from the Eindhoven Cancer Registry. This
southern region of the Netherlands is served by 10 hospitals
each serving a population between 150,000 and 250,000 peo-
ple. Data on statin use (simvastatin, pravastatin, cerivastatin,fluvastatin, atorvastatin, and rosuvastatin) was derived from
the PHARMO database network (PHARMO, Netherlands). The
central patient database of the PHARMO record linkage system
has recently been linked to the Eindhoven Cancer Registry
database; this is described in detail by Van Herk-Sukel et al.14
Information about cause of death was obtained from Statistics
Netherlands. Formalin-fixed paraffin-embedded tissue blocks
were retrieved from 1026 patients with colon cancer who had a
surgical resection between 2002 and 2008.15 Rectal cancers
were not included because many of these tissue specimens will
have been exposed to preoperative radiotherapy, which may
influence tumor molecular characteristics. Twenty-seven
patients with more than 1 colon tumor at the time of diag-
nosis were excluded for this study; thus the total cohort con-
sisted of 999 patients.
TMA Production
Three 1.0-mm diameter cores were obtained from formalin-
fixed paraffin-embedded tumor blocks and transferred into a
receiver paraffin block using the TMA Master (3D Histech,
Budapest, Hungary) as previously described.15 Representative
tumor sites were identified by 2 independent researchers using
H&E-stained sections (with a qualified pathologist confirming
the identification of the tumor).
Immunohistochemistry and TMA Scoring System
Determination of microsatellite stability status by immu-
nohistochemical analysis has been previously described.15
SMAD4 and BMP receptors were stained according to previ-
ously described methods.16 Examples of tumor core stainings
are shown in Supplementary Figure 1. Scoring was performed
in a blinded fashion by 2 investigators (P.V. and J.H.) inde-
pendently according to previously described methods.16 Three
cores per tumor were analyzed and an average score per tumor
was calculated. The concordance between investigators was
87% (k ¼ 0.70, 95% confidence interval [CI] 0.604–0.796).
Final scoring was reached by consensus. The tumors were
divided in “intact BMP signaling” and “non-intact BMP
signaling” based on the expression of SMAD4, BMPR1a,
BMPR1b, and BMPR2. The tumor was designated as having
“non-intact BMP signaling” if either SMAD4 or one of the BMP
receptors scored negative.
KRAS Mutation Analysis
DNA was extracted from 2.0-mm diameter cores taken
randomly from 663 of the 999 blocks, as previously
described.15 For determination of KRAS mutations status,
hydrolysis probe assays were performed for the major known
mutations (hotspots) in codon 12 and 13 for KRAS; c.34G>A;
p.G12S, c.34G>C; p.G12R, c.34G>T; p.G12C, c.35G>A; p.G12D,
c.35G>C; p.G12A, c.35G>T; p.G12V, c.38G>A; p.G13D and
c.37G>T; p.G13C, as previously described.15 Hydrolysis probe
assays were analyzed using quantitative polymerase chain
reaction analysis software (CFX manager version 3/0, Bio-Rad,
Hercules, CA). Mutation detection was performed blindly by 2
independent observers (M.S.R. and R.E.).
Statistics
Definition of statin user. Statistical analyses were
performed using the statistical packages SPSS (version 20.0 for
Table 1.Baseline Characteristics of the Colon Cancer












Male 505 (50.6) 379 (48.0) 126 (60.0) .002
Female 494 (49.4) 410 (52.0) 84 (40.0)
Age
<65 342 (34.2) 282 (35.7) 60 (28.6) <.001
66–74 304 (30.4) 211 (26.7) 93 (44.3)
75 353 (35.4) 296 (37.5) 57 (27.1)
Year of diagnosis
2002–2004 451 (45.2) 354 (44.9) 97 (46.2) .732
2005–2007 548 (54.8) 435 (55.1) 113 (53.8)
Disease stage
I 138 (13.8) 99 (12.6) 39 (18.6) .005
II 402 (40.2) 308 (39.0) 94 (44.8)
III 287 (28.7) 231 (29.3) 56 (26.7)
IV 169 (16.9) 149 (18.9) 20 (9.5)
Unknown 3 (0.3) 2 (0.3) 1 (0.5)
Comorbidity
No 443 (44.3) 401 (50.8) 42 (20.0) <.001
Yes 556 (55.7) 388 (49.2) 168 (80.0)
Microsatellite status
MSI 90 (9.0) 70 (8.9) 20 (9.5) .727
MSS 870 (87.1) 690 (87.5) 180 (85.7)
Unknown 39 (3.9) 29 (3.7) 10 (4.8)
Chemotherapy
No 691 (69.2) 542 (68.7) 149 (71.0) .529
Yes 308 (30.8) 247 (31.3) 61 (29.0)
MSI, microsatellite instable tumors; MSS, microsatellite
stable tumors.
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(version 12 for windows, StataCorp LLC, College Station, TX).
A P value of <.05 was considered statistically significant.
The vital status of patients (alive/dead) was identified via
medical records or through linking the Eindhoven Cancer
registry data with the municipal population registries that
have information on the vital status (alive or deceased). Follow-
up started 30 days from diagnosis of colon cancer (T0), and
was ended January 2012 or at the date of death. Patients who
died within 30 days after diagnosis were excluded from the
survival analyses (2.4%). Statin non-users were classified as
those who never had a prescription for statin or had a pre-
scription for less than 14 consecutive days after diagnosis of
colon cancer. Statin users were defined as those who had been
given a prescription for statins for 14 days or more after a
colon cancer diagnosis.
Time-dependent survival analyses. A time-
dependent exposure survival analysis for Overall Mortality
(deaths from any cause) and Cancer-Specific Mortality (deaths
from cancer) was performed in which patients were defined as
non-users from T0 to the first use and users from first use to
the end of the follow-up. A parametric survival model with an
exponential (Poisson) distribution was used. Secondly, a Cox
proportional hazard model was used with statin use as a time-
varying covariate to confirm the analyses. Adjustments for
potential confounders were made for sex, age (continuous),
stage (pathologic stage or clinical stage when pathologic stage
was unknown), adjuvant chemotherapy (yes/no), grade, year
of incidence, microsatellite status, and comorbidity (yes/no).
Comorbidities included respiratory disease, cardiovascular
disease, digestive disease, musculoskeletal disease, neurologic
disease, or endocrine disease. Subgroup analyses were per-
formed for sex, age, stage, grade, chemotherapy, aspirin use
after diagnosis, and frequent use of statin (3, 5, or 7
prescriptions). Frequent users were defined as patients who
had a given number (or more) consecutive repeat pre-
scriptions for statins. User time started after the completion of
the 3, 5, or 7 prescriptions. Survival time of patients who had
<3, 5, or 7 refills and time before the prescription
requirements of the frequent users was classified as non-user
time in this analysis.
Sensitivity analyses for ACE inhibitors and
benzodiazepines. A sensitivity analyses was performed to
assess the association of 2 other groups of medicine,
benzodiazepines and ACE inhibitors, and survival. For this, the
same methodology as for statin use was followed and a time-
dependent parametric survival model with an exponential
(Poisson) distribution was used, in which patients were defined
as non-users from T0 to the first use and users from first use to
the end of the follow-up. Adjustments for potential confounders
were made for sex, age (continuous), stage (pathologic stage or
clinical stage when pathologic stage was unknown), adjuvant
chemotherapy (yes/no), grade, year of incidence, microsatellite
status, and comorbidity (yes/no). An extra analysis was per-
formed excluding statin users from the group of post-diagnosis
ACE inhibitors users.
A lag of 6 months. In another analysis, a lag of 6 months
after diagnosis was introduced to reduce any bias in prescrib-
ing that may arise because of impending death, although our
definition of a statin user was specifically chosen to minimize
this sort of bias caused by disease progression.Molecular subtypes. Finally, differential associations of
statin use with cancer-specific mortality by tumor molecular
subtype were investigated by subgroup analyses for intact BMP
signaling status and KRAS mutation status followed by an
interaction analysis.
Results
Statin use After Colon Cancer Diagnosis
and Survival
In total, 999 colon cancer patients were included in this
study. Table 1 shows the characteristics of the population
according to statin use or non-use after diagnosis and
Figure 1 shows a flow diagram of the patient inclusion in the
various analyses. In this cohort, 21.0% (210/999) were
defined as statin users after diagnosis. During follow-up
until January 2012, 465 deaths were recorded, of whom
69 were statin users (32.9% of statin users) and 396 were
nonusers (50.2% of nonusers). Statin users were predomi-
nately male, older age, and had more comorbidities.
Furthermore, tumors found in statin users have a lower
stage than tumors found in non-users (P ¼ .005). The mean
and median duration of prescriptions was 76.6 and 90 days,
respectively, and the mean number of prescriptions per
patient was 23 (range, 1–215). Overall, 51.7% of the
Figure 1. Flow diagram of the patient inclusion in the various analyses.





ATpatients showed no discontinuation over the study period
and 36.6% stopped for 30 days or less, which is not
considered as discontinuation. Overall, 11.7% of the pa-
tients discontinued statin use for more than 30 days and 7%
more than 90 days. Median follow-up of the cohort was 3.3
years (range, 0.01–8.27 years), with a median follow-up of
4.1 years (range, 0.001–7.94 years) for patients who werealive during the study period. Median first start of post-
diagnosis statin use was at 1.9 years (range, 0.005–6.31
years). There were 396 deaths in 789 non-users of statins
and 69 deaths in 210 patients who used statins.
The 5-year overall survival for non-users was 54.6%
(95% CI 50.8–58.1) and 65.7% (95% CI 57.8–72.4) for
statin users. Statin use after diagnosis was significantly
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with a rate ratio (RR) of 0.65 (95% CI 0.50–0.84, P ¼ .001)
and death from cancer; RR of 0.64 (95% CI 0.47–0.85,
P ¼ .002). When adjusted for potential confounders, this
effect remained with an adjusted RR of 0.67 for overall
survival (95% CI 0.51–0.87, P ¼ .003) and an adjusted RR
of 0.66 for CSS (95% CI 0.49–0.89, P ¼ .007) (Table 2).
Supplementary Table 1 shows the RRs for variables used
in the multivariable analyses other than statin use. Sub-
group analyses by stage at diagnosis showed no associa-
tion for mortality in stage I (adjusted RR 1.42; 95% CI
0.50–4.02, P ¼ .90) and stage III (adjusted RR 1.10; 95% CI
0.65–1.88, P ¼ .71), but showed an association between
statin use and mortality for stage II (adjusted RR 0.45;
95% CI 0.24–0.87, P ¼ .02) and stage IV (adjusted RR 0.43;
95% CI 0.25–0.76, P ¼ .004). The interaction test for
mortality and stage is P < .01. Interestingly, frequent use
of statins, especially more than 7 refills, further reducedTable 2.Rate Ratio for Death (Time-Dependent
Analysis Overall Mortality and Cancer-Specific











Deaths from any cause 396 69
Rate ratio (95% CI) 1.0 (reference) 0.65 (0.50–0.84) .001
Adjusted rate ratio
(95% CI)b
1.0 (reference) 0.67 (0.51–0.87) .003
Deaths from cancer 311 53
Rate ratio (95% CI) 1.0 (reference) 0.64 (0.47–0.85) .002
Adjusted rate ratio
(95% CI)b
1.0 (reference) 0.66 (0.49–0.89) .007
Stage subgroups (CSS)
Stage I 1.0 (reference) 1.42 (0.50–4.02) .51
Stage II 1.0 (reference) 0.45 (0.24–0.87) .02
Stage III 1.0 (reference) 1.10 (0.65–1.88) .71
Stage IV 1.0 (reference) 0.43 (0.25–0.76) .004
Statin frequent use 3 prescriptions
Patients 802 197
Deaths from cancer 313 51
Rate ratio (95% CI) 1.0 (reference) 0.63 (0.47–0.85) .002
Adjusted rate ratio
(95% CI)b
1.0 (reference) 0.72 (0.52–1.00) .049
Statin frequent use (5 prescriptions)
Patients 815 184
Deaths from cancer 319 45
Rate ratio (95% CI) 1.0 (reference) 0.57 (0.42–0.78) <.001
Adjusted rate ratio
(95% CI)b
1.0 (reference) 0.65 (0.46–0.91) .012
Statin frequent use (7 prescriptions)
Patients 826 173
Deaths from cancer 322 42
Rate ratio (95% CI) 1.0 (reference) 0.56 (0.41–0.78) <.001
Adjusted rate ratio
(95% CI)b
1.0 (reference) 0.63 (0.44–0.89) .009
aStatin use after diagnosis.
bAdjusted for sex, age, comorbidity, year of incidence,
histologic grade, stage, microsatellite status, chemotherapy,
and aspirin use.risk of death, with an adjusted RR of 0.63 (95% CI
0.44–0.89, P ¼ .009).
We have previously shown that low-dose aspirin use
after diagnosis was associated with a survival benefit in this
cohort.15 Therefore, we performed a further analysis in
patients that only used statins or only used aspirin or a
combination of both (Table 3). Compared with patients who
used neither aspirin or statins after diagnosis, isolated statin
use and isolated aspirin use were both significantly associ-
ated with a reduced risk of death from cancer, with an
adjusted RR of 0.48 (95% CI 0.31–0.73) for isolated statin
use and 0.54 (95% CI 0.35–0.85) for isolated aspirin use. A
combination of both statin and aspirin use was not signifi-
cantly associated with mortality; adjusted RR of 0.69 (95%
CI 0.46–1.03). The notion that statins act independently of
aspirin use is further confirmed by the fact that statin use
was significantly associated with a reduced risk of death in
patients who did not use aspirin after diagnosis (adjusted
RR 0.51, 95% CI 0.33–0.79, P ¼ .003).
Including a lag of 6 months was associated with a
reduced risk of death from cancer with a RR of 0.64 (95% CI
0.47–0.85, P ¼ .002) and an adjusted RR of 0.66 (95% CI
0.48–0.89, P ¼ .007).
ACE Inhibitors and Benzodiazepines
We performed sensitivity analyses with post-diagnosis
ACE inhibitor, a group of cardiovascular medicines not
associated with colon cancer survival, and observed a sig-
nificant RR of 0.75 (95% CI 0.59–0.96, P ¼ .024), but a non-
significant adjusted RR of 0.81 (95% CI 0.62–1.05, P ¼ .114).
When excluding statin users, ACE inhibitor use has a RR of
0.98 (95% CI 0.70–1.38, P ¼ .93). We also analyzed a
completely different class of drugs; benzodiazepines. These
were not associated with improved survival (P ¼ .03).
Statin use, Survival, and KRAS Mutations
KRAS mutation status (wild-type/mutation) was estab-
lished in 98% (652/663) of the tumor cores that were
randomly taken from the 999 original tumor cores. There
were no differences in baseline characteristics betweenTable 3.Rate Ratio for Cancer-Specific Mortality










Aspirin or statin use
No aspirin or statin use 711 288 1.0 (reference) .0002
Statin use, no aspirin 106 23 0.48 (0.31–0.73)
Aspirin use, no statin 78 23 0.54 (0.35–0.85)
Both aspirin and
statin use
104 30 0.69 (0.46–1.03)
Aspirin non-users
Statin non-users 711 288 1.0 (reference) .003
Statin users 106 23 0.51 (0.33–0.79)
Table 4.Rate Ratio for Cancer-Specific Mortality (Time-
Dependent Analysis), According to Tumor KRAS
Mutation Statuse, BMP Signaling Pathway Statusd









Deaths from cancer 311 53
Adjusted rate ratio
(95% CI)a,b
1.0 (reference) 0.66 (0.49–0.89) .007
Adjusted hazard ratio
(95% CI)a,c
1.0 (reference) 0.71 (0.53–0.97) .032
KRAS Wild-type cancers
Patients 317 105
Deaths from cancer 122 31
Adjusted rate ratio
(95% CI)a,b
1.0 (reference) 0.82 (0.54–1.25) .35
Adjusted hazard ratio
(95% CI)a,c
1.0 (reference) 0.86 (0.56–1.31) .48
KRAS Mutant cancers
Patients 173 57
Deaths from cancer 74 15





ATpatients of whom the DNA was extracted and the KRAS
mutation status was established and those in which this was
not successful. A KRAS mutation was found in 35.3% (230/
652) of the samples, which shows a prevalence that is in
accord with other studies.17 Supplementary Table 2 sum-
marizes the clinical characteristics of the patients based on
the KRAS mutation status and statin use. Statin use was not
significantly different in patients with KRAS wild-type tu-
mors (24.9%) and KRASmutated tumors (24.8%). The effect
of KRAS mutation status on the survival benefit associated
with statin use after diagnosis was analyzed. Statin use after
diagnosis was not associated with a reduced risk of death
from cancer in KRAS wild-type tumors (adjusted RR 0.82;
95% CI 0.54–1.25, P ¼ .35) or KRAS mutated-tumors
(adjusted RR 0.59; 95% CI 0.33–1.08, P ¼ .086); test for
interaction P ¼ .4566 (Table 4). A Cox proportional hazard
model confirmed the results of the Poisson model (adjusted
RR for KRAS mutant cancers, 0.64; 95% CI 0.35–1.17,
P ¼ .148). An interaction analysis showed no statistically
significant difference between the 2 molecular tumor sub-
types (P value for interaction ¼ .457). Supplementary
Table 4 shows the results based on overall mortality.Adjusted rate ratio
(95% CI)a,b
1.0 (reference) 0.59 (0.33–1.08) .086
Adjusted hazard ratio
(95% CI)a,c
1.0 (reference) 0.64 (0.35–1.17) .148
Intact BMP-signaling
Patients 376 81
Deaths from cancer 124 18
Adjusted rate ratio
(95% CI)a,b
1.0 (reference) 0.39 (0.22–0.68) .001
Adjusted hazard ratio
(95% CI)a,c
1.0 (reference) 0.42 (0.24–0.74) .003
Non-intact BMP-signaling
Patients 398 121
Deaths from cancer 179 33
Adjusted rate ratio
(95% CI)a,b
1.0 (reference) 0.81 (0.55–1.21) .31
Adjusted hazard ratio
(95% CI)a,c
1.0 (reference) 0.89 (0.60–1.33) .58
Intact BMP-signaling and wild-type cancers
Patients 150 44
Deaths from cancer 43 12
Adjusted rate ratio
(95% CI)a,b
1.0 (reference) 0.81 (0.40–1.62) .55
Intact BMP-signaling and mutant cancers
Patients 89 18
Deaths from cancer 34 6
Adjusted rate ratio
(95% CI)a,b
1.0 (reference) 0.59 (0.22–1.57) .29
aAdjusted for sex, age, comorbidity, year of incidence, histo-
logic grade, stage, microsatellite status, and chemotherapy.
bPoisson model.
cCox model.
dKRAS analyses: 663 of 999 patients analysed; 652 of 663
samples included.
eBMP analyses: 976 of 999 samples included.Statin use, Survival, and BMP Signaling
Analysis of BMP signaling pathway components was
performed on 976 tumor sections (97.7% of total). Loss of
2.3% of the tumor sections in this analysis was a conse-
quence of staining artifacts and loss of material during the
staining procedure. The tumors were categorized as having
either “intact BMP signaling” or “non-intact BMP signaling”
based on the expression levels of SMAD4 and the BMP re-
ceptors (see Materials and Methods section for a full
description of the scoring system). We presumed that the
BMP signaling pathway was intact when all components
were expressed and that the BMP signaling pathway was
“non-intact” when there was absence of expression of one of
the components. In this cohort, 519 patients (53.2%)
showed non-intact BMP signaling in their tumor sections
and 457 patients (46.8%) showed intact BMP signaling.
Supplementary Table 3 summarizes the clinical character-
istics of the patients based on BMP signaling status and
statin use; 23.3% of patients in whom we observed non-
intact BMP signaling in the tumor sections were statin
users and 17.7% of patients with intact BMP signaling were
statin users. Statin users had more comorbidities in both
groups. Within the “intact BMP signaling” group, low-stage
tumors (P ¼ .012) were more prevalent in statin users
than in statin non-users.
To test our hypothesis that statins act via the BMP
pathway in colon cancer prevention, we analyzed the effect
of BMP signaling pathway status on statin-associated pa-
tient survival (Table 4). The significant reduction in risk of
death associated with statin use after diagnosis was more
prominent in the group of tumors that exhibited intact BMP
component expression with an adjusted RR of 0.39 (95% CI
0.22–0.68, P ¼ .001) than for patients with tumors in which
we observed a non-intact BMP signaling pathway (adjusted
RR 0.81; 95% CI 0.40–1.62, P ¼ .55). A Cox proportionalhazard model confirmed the results of the Poisson model
(adjusted RR 0.42; 95% CI 0.24–0.74, P ¼ .003). An inter-
action analysis showed a statistically significant difference
between the 2 molecular tumor subtypes (P value for
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results based on overall mortality.Discussion
In this large observational study, we show in our cohort
that statin use initiated or continued after a diagnosis of
colon cancer is associated with a significantly reduced risk
of death from any cause with an RR of 0.65 and death from
cancer with an RR of 0.64. To test for associations between
the molecular tumor subtype and the effect of statins on
colon cancer survival, we analyzed both the KRAS mutation
status and the protein expression of multiple elements of
the BMP signaling pathway in the tumor samples. We have
previously performed similar analyses of the BMP pathway
in both pancreatic ductal adenocarcinoma and colorectal
cancer.16,18 We found that the association between statins
and survival did not differ in KRAS mutant versus KRAS
wildtype tumor, but the survival benefit associated with
statin use was stronger in tumors with an intact BMP
signaling pathway. This is in accordance with findings from
our previous in vitro and rodent studies showing that sta-
tins are only effective antitumor agents in tumors where the
BMP signaling pathway is functional.7,11
Statins may be an attractive candidate for use as adju-
vant therapy in colorectal cancer because they are already
widely used and well tolerated.19,20 Statins have previously
been shown to reduce the incidence of colorectal cancer. A
large retrospective study published in 2005 assessing the
association between statin use and the incidence of colo-
rectal cancer showed a 47% reduction in the risk of
developing colorectal cancer.5 Although several subsequent
studies have failed to confirm this effect,21,22 a recent meta-
analysis combining 42 large observational studies, case-
control studies, and randomized control trials showed an
overall risk reduction of 10% for the development of colo-
rectal cancer in statin users, providing more evidence for
the antitumor potential of statins.23
Despite the large number of trials that have investigated
the association between the incidence of colorectal cancer
and statin use, relatively few studies have investigated the
effect of adjuvant statin use on patient survival in colorectal
cancer. A study from Scotland that included 308 patients
with colorectal cancer found a non-significant reduction in
colorectal cancer-specific mortality in statin users.24 An
American study of 407 patients with rectal cancer who
received chemo-radiotherapy also found a non-significant
reduction in cancer-specific mortality in statin users
before and after surgery.25 Another American study in 842
patients with stage III colon cancer did not detect any as-
sociation between patient-reported statin use after diag-
nosis and cancer recurrence26; and a Dutch study found no
association between statin use, KRAS mutation status, and
metastatic colorectal cancer progression-free survival after
chemotherapy.27 Some of these studies investigated specific
colorectal cancer subgroups25–27 or had limitations, such as
relatively small size,24–27 measurement of medication use at
1 time-point,26 and potential for immortal time bias.24 In the
biggest study to date from the UK, a cohort of 7657 patientswith colorectal cancer were analyzed using time-dependent
Cox regression models. Statin use post-diagnosis was asso-
ciated with a significant reduction in overall survival.28 This
is consistent with our findings of a strong association be-
tween statin use and overall patient survival. The strengths
of our study are the use of registered drug prescriptions to
ascertain drug exposure rather than patient questionnaires,
a relatively large cohort of 999 patients, molecular analysis
of tumor tissue, and analysis of the effect of combined
exposure to aspirin and statins. This is particularly inter-
esting in the light of conflicting evidence as to whether a
combination of aspirin and statins may be more effective
than one or the other alone.29–32
A recently published study with this cohort showed an
association between low-dose aspirin use after diagnosis
and improved survival.15 Interestingly, isolated use of either
statins or aspirin after diagnosis are both associated with an
improved survival in patients, indicating that statins and
aspirin improve patient outcome independently. Although
there is considerable in vitro evidence that a combined
therapy of statins and aspirin could be beneficial,33 we
could not find a synergistic or additive effect of statin
combined with aspirin use. Separating this cohort based on
statin and/or aspirin use results in a relative small number
of patients per group; a larger cohort will be needed to
assess the additive effect of combination therapy.
The molecular mechanisms responsible for the anti-
tumor effects of statins on colorectal cancer are not fully
understood. As mentioned in our introduction, several
mechanisms have been proposed, 2 of which we have
investigated in this study, namely that statins act on KRAS
by influencing its prenylation and that statins act by acti-
vating the BMP signaling pathway.
Firstly, we investigated the influence of KRAS mutation
status on the association between statin use and patient
survival. There is evidence that statins act through the in-
hibition of the Ras/Raf pathway from studies performed in
cancer cell line cells and xenograft mouse models. For
example, it has been shown that lovastatin inhibits the Raf/
MEK/ERK pathway in leukemia cells, resulting in
apoptosis,34 and that atorvastatin can disrupt KRAS/Raf
complexes, leading to inhibition of AKT and ERK in non-
small cell lung cancer cells.35 The most clinically relevant
data came from a study showing that simvastatin could
overcome cetuximab resistance in colon cancer cell line cells
harboring KRAS mutations and not in cells with BRAF mu-
tations, implying that only KRAS mutant cancers would
benefit from statin treatment.36 We did not see a difference
in the association between statin and survival comparing
KRAS WT cancers and KRAS mutant cancers in our cohort.
There was no significant reduction in risk of death associ-
ated with statin use in either group, although the results in
KRAS mutant tumors nearly reached significance. The
reason for the loss of a significant protective effect of statins
when separating the cancers based on the KRAS mutation
status is probably the low number of cancers in each group.
A larger cohort is therefore necessary to adequately assess
the influence of KRASmutation status on the survival benefit
associated with statin use. Our data is consistent with 2





ATstudies that have found no association between the KRAS
mutation status, statin use, and colorectal cancer sur-
vival.26,27 However, in these studies, statin use after diag-
nosis was not associated with improved survival in
colorectal cancer overall, in contrast to our study, making
the studies difficult to compare.
Secondly, we investigated the influence of tumor
expression of elements of the BMP signaling pathway on the
association between statin use and patient survival. The
BMP signaling pathway functions as a tumor suppressor in
colorectal cancer, inducing cell differentiation and apoptosis
of colonic epithelial cells and negatively regulating WNT
signaling.37,38 In a screen of 30,000 compounds, lovastatin
and simvastatin were the 2 most potent enhancers of BMP2
expression in bone.10 We have subsequently shown that
statins inhibit colorectal cancer cell proliferation and induce
apoptosis through increasing BMP2 expression, but only
when the BMP pathway is fully functional.7 BMP ligands
bind to a complex of transmembrane serine threonine ki-
nase receptors type 1 and 2, resulting in phosphorylation
and activation of the BMP receptor type 2 (BMPR2). The
activated BMPR2 activates BMP receptor type 1 (BMPR1a
and BMPR1b), which phosphorylate the receptor-associated
SMADS (SMAD1, 5, and 8) that subsequently complex with
SMAD4 and translocate to the nucleus to regulate gene
transcription. When expression of either SMAD4 or any one
of the BMP receptors is lost, the canonical BMP signaling
pathway cannot be activated. We assessed the expression
levels of SMAD4, BMPR1a, BMPR1b, and BMPR2 using
immunohistochemistry as we have performed previously. In
this cohort, statins are associated with a reduced risk of
death in cancers that express both SMAD4 and BMP
receptors (described in the Results section as intact BMP
signaling), suggesting that the anticancer benefit of statin
may be BMP-dependent. Because this is the first study to
investigate the role of the BMP signaling pathway in the
association between statins and colon cancer mortality,
comparison with other studies is not possible. These results
require confirmation in further cohorts.
There are several limitations to the study. This is a
retrospective study in which randomization was not
possible. Immortal time bias was avoided by using a time-
dependent model, but confounding by disease progression
may still occur. Next to a parametric survival model with
exponential (Poisson) distribution, a Cox proportional haz-
ard model was used with statin use as a time varying co-
variate to confirm the analyses. Our methodology for
defining user and non-user time will minimize confounding
by disease progression. This can arise where poor prognosis
or advanced disease influences statin usage, with statins
being stopped in these patients potentially leading to a
spuriously lower number of deaths in statin users. This
depends on how “statin user” is defined and how statin user
time is accrued. In our study, user time is accrued after the
first prescription, even if a patient subsequently stopped
using statins, effectively avoiding this bias.
Reverse causation was further addressed by applying a
lag of exposure of 6 months, which also resulted in a
significant difference.Because reduced risk of death could potentially be
explained by reductions in cardiovascular events in statin
users, we also analyzed risk of death from any cause. Statin
use can also be a sign of compliance. Consistent statin use
could therefore be a surrogate marker for health con-
sciousness, which can cause a “healthy user bias” in studies
like ours. We observed similar effects of aspirin and statins
on colon cancer mortality, implying that both medications
are protective or that a hidden factor connecting aspirin and
statins is responsible. However, analyses with ACE
inhibitors and benzodiazepines proved that this was not the
case.
There were differences in baseline characteristics
between statin users and statin non-users that could have
confounded our results: statin users were more often male,
were older, had more comorbidity, and had earlier stage
tumors. However, when adjusting for these confounders, a
clear association between statin use and a better prognosis
remained. However, residual confounding by unknown
factors could still influence the results. Lastly, the assess-
ment of active BMP signaling is not perfect. The fact that all
the components of BMP signaling are present or the fact 1
or more components are missing does not necessarily mean
that there is or isn’t active BMP signaling. Because of the
complex matrix of downstream signaling targets, which can
be activated or inhibited by canonical and/or noncanonical
BMP signaling, it is difficult to find a suitable (surrogate
marker) for BMP signaling activity. Phospho-SMAD1, 5, or 8
are commonly used in vitro to determine BMP signaling
activity, but phospho-proteins are very sensitive to tissue
processing and fixation, making the assessment of expres-
sion levels in human tissue inaccurate.39 In another study
using human colon cancer tissue, we found nuclear
p-SMAD1, 5, or 8 without the presence of SMAD4, which is
thought to be necessary for nuclear translocation of
p-SMAD1, 5, or 8. We cannot evaluate whether this is the
result of tissue processing or SMAD4-independent
non-canonical BMP signaling. We do know that loss of
SMAD4 in colon cancer is associated with a poor patient
survival and negative nuclear p-SMAD1, 5, or 8 staining
is not.39
In conclusion, in our cohort statin use after diagnosis is
associated with a reduced risk of death in patients with
colon cancer. More importantly, this reduction was most
pronounced in patients whose tumors retain expression of
BMP signaling pathway components. In the future, BMP
signaling functionality may serve as a predictive biomarker
to select patients for adjuvant statin therapy. However, our
data are preliminary and other studies, preferably
randomized clinical trials, are needed to confirm the
beneficial effects of statins on colon cancer survival and
BMP signaling as a predictive biomarker.Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at http://dx.doi.org/10.1053/
j.gastro.2017.05.011.
478 Voorneveld et al Gastroenterology Vol. 153, No. 2
CLINICAL
ATReferences
1. Howlader N, Noone NA, Krapcho M, et al, eds. SEER
cancer statistics review, 1975-2010. Bethesda, MD:
National Cancer Institute, April 2013. Available at: http://
seer.cancer.gov/csr/1975_2010/.
2. Bastiaannet E, Sampieri K, Dekkers OM, et al. Use of
aspirin postdiagnosis improves survival for colon cancer
patients. BR J Cancer 2012;106:1564–1570.
3. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival
after diagnosis of colorectal cancer. JAMA 2009;
302:649–658.
4. Downs JR, Clearfield M, Tyroler HA, et al. Air Force/
Texas Coronary Atherosclerosis Prevention Study
(AFCAPS/TEXCAPS): additional perspectives on tolera-
bility of long-term treatment with lovastatin. Am J Cardiol
2001;87:1074–1079.
5. Poynter JN, Gruber SB, Higgins PD, et al. Statins and the
risk of colorectal cancer. N Engl J Med 2005;352:
2184–2192.
6. Agarwal B, Halmos B, Feoktistov AS, et al. Mechanism
of lovastatin-induced apoptosis in intestinal epithelial
cells. Carcinogenesis 2002;23:521–528.
7. Kodach LL, Bleuming SA, Peppelenbosch MP, et al. The
effect of statins in colorectal cancer is mediated through
the bone morphogenetic protein pathway. Gastroenter-
ology 2007;133:1272–1281.
8. Konstantinopoulos PA, Karamouzis MV,
Papavassiliou AG. Post-translational modifications and
regulation of the RAS superfamily of GTPases as anti-
cancer targets. Nat Rev Drug Discov 2007;6:541–555.
9. Baldus SE, Schaefer KL, Engers R, et al. Prevalence and
heterogeneity of KRAS, BRAF, and PIK3CA mutations in
primary colorectal adenocarcinomas and their corre-
sponding metastases. Clin Cancer Res 2010;16:790–799.
10. Mundy G, Garrett R, Harris S, et al. Stimulation of bone
formation in vitro and in rodents by statins. Science
1999;286:1946–1949.
11. Kodach LL, Jacobs RJ, Voorneveld PW, et al. Statins
augment the chemosensitivity of colorectal cancer cells
inducing epigenetic reprogramming and reducing colo-
rectal cancer cell ’stemness’ via the bone morphogenetic
protein pathway. Gut 2011;60:1544–1553.
12. Hardwick JC, Kodach LL, Offerhaus GJ, van den
Brink GR. Bone morphogenetic protein signalling in
colorectal cancer. Nat Rev Cancer 2008;8:806–812.
13. Kodach LL, Wiercinska E, de Miranda NF, et al. The bone
morphogenetic protein pathway is inactivated in the
majority of sporadic colorectal cancers. Gastroenter-
ology 2008;134:1332–1341.
14. van Herk-Sukel MP, van de Poll-Franse LV,
Lemmens VE, et al. New opportunities for drug outcomes
research in cancer patients: the linkage of the Eindhoven
Cancer Registry and the PHARMO Record Linkage
System. Eur J Cancer 2010;46:395–404.
15. Reimers MS, Bastiaannet E, Langley RE, et al. Expres-
sion of HLA class I antigen, aspirin use, and survival after
a diagnosis of colon cancer. JAMA 2014;174:732–739.
16. Voorneveld PW, Kodach LL, Jacobs RJ, et al. Loss of
SMAD4 alters BMP signaling to promote colorectalcancer cell metastasis via activation of Rho and ROCK.
Gastroenterology 2014;147:196–208.
17. Yoon HH, Tougeron D, Shi Q, et al. KRAS codon 12 and
13 mutations in relation to disease-free survival in BRAF-
wild-type stage III colon cancers from an adjuvant
chemotherapy trial (N0147 alliance). Clin Cancer Res
2014;20:3033–3043.
18. Voorneveld PW, Stache V, Jacobs RJ, et al. Reduced
expression of bone morphogenetic protein receptor IA in
pancreatic cancer is associated with a poor prognosis.
Br J Cancer 2013;109:1805–1812.
19. Downs JR, Clearfield M, Weis S, et al. Primary prevention
of acute coronary events with lovastatin in men and
women with average cholesterol levels. JAMA 1998;
279:1615–1622.
20. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin
therapy, LDL cholesterol, C-reactive protein, and coro-
nary artery disease. N Engl J Med 2005;352:29–38.
21. Coogan PF, Smith J, Rosenberg L. Statin use and risk of
colorectal cancer. J Natl Cancer Inst 2007;99:32–40.
22. Jacobs EJ, Newton CC, Thun MJ, Gapstur SM. Long-
term use of cholesterol-lowering drugs and cancer
incidence in a large United States cohort. Cancer Res
2011;71:1763–1771.
23. Liu Y, Tang W, Wang J, et al. Association between statin
use and colorectal cancer risk: a meta-analysis of 42
studies. Cancer Causes Control 2014;25:237–249.
24. Lakha F, Theodoratou E, Farrington SM, et al. Statin use
and association with colorectal cancer survival and risk:
case control study with prescription data linkage. BMC
Cancer 2012;12:487.
25. Mace AG, Gantt GA, Skacel M, et al. Statin therapy is
associated with improved pathologic response to
neoadjuvant chemoradiation in rectal cancer. Dis Colon
Rectum 2013;56:1217–1227.
26. Ng K, Ogino S, Meyerhardt JA, et al. Relationship
between statin use and colon cancer recurrence and
survival: results from CALGB 89803. J Natl Cancer Inst
2011;103:1540–1551.
27. Krens LL, Simkens LHJ, Baas JM, et al. Statin use is not
associated with improved progression free survival in
cetuximab treated KRAS mutant metastatic colorectal
cancer patients: results from the CAIRO2 Study. PLoS
ONE 2014;9:e112201.
28. Cardwell CR, Hicks BM, Hughes C, et al. Statin use after
colorectal cancer diagnosis and survival: a population-
based cohort study. J Clin Oncol 2014;32:3177–3183.
29. Vinogradova Y, Hippisley-Cox J, CouplandC, et al. Risk of
colorectal cancer in patients prescribed statins, nonste-
roidal anti-inflammatory drugs, and cyclooxygenase-2
inhibitors: nested case-control study. Gastroenterology
2007;133:393–402.
30. Hoffmeister M, Chang-Claude J, Brenner H. Individual
and joint use of statins and low-dose aspirin and risk of
colorectal cancer: a population-based case-control
study. Int J Cancer 2007;121:1325–1330.
31. Shadman M, Newcomb PA, Hampton JM, et al. Non-
steroidal anti-inflammatory drugs and statins in relation
to colorectal cancer risk. World J Gastroenterol 2009;
15:2336–2339.





AT32. Agarwal B, Rao CV, Bhendwal S, et al. Lovastatin aug-
ments sulindac-induced apoptosis in colon cancer cells
and potentiates chemopreventive effects of sulindac.
Gastroenterology 1999;117:838–847.
33. Xiao H, Yang CS. Combination regimen with statins and
NSAIDs: a promising strategy for cancer chemopreven-
tion. Int J Cancer 2008;123:983–990.
34. Wu J, Wong WW, Khosravi F, et al. Blocking the Raf/
MEK/ERK pathway sensitizes acute myelogenous leu-
kemia cells to lovastatin-induced apoptosis. Cancer Res
2004;64:6461–6468.
35. Chen J, Bi H, Hou J, et al. Atorvastatin overcomes
gefitinib resistance in KRAS mutant human non-small cell
lung carcinoma cells. Cell Death Dis 2013;4:e814.
36. Lee J, Lee I, Han B, et al. Effect of simvastatin on
cetuximab resistance in human colorectal cancer with
KRAS mutations. J Natl Cancer Inst 2011;103:674–688.
37. Hardwick JC, van den Brink GR, Bleuming SA, et al.
Bone morphogenetic protein 2 is expressed by, and acts
upon, mature epithelial cells in the colon. Gastroenter-
ology 2004;126:111–121.38. He XC, Zhang J, Tong WG, et al. BMP signaling inhibits
intestinal stem cell self-renewal through suppression of
Wnt-beta-catenin signaling. Nat Genet 2004;36:
1117–1121.
39. Voorneveld PW, Jacobs RJ, De Miranda NF, et al. Eval-
uation of the prognostic value of pSMAD immunohisto-
chemistry in colorectal cancer. eur J Cancer Prev 2013;
22:420–424.
Author names in bold designate shared co-first authors.
Received April 15, 2015. Accepted May 8, 2017.
Reprint requests
Address requests for reprints to: James C. H. Hardwick, MD, PhD,
Department of Gastroenterology and Hepatology, Leiden University
Medical Centre, Albinusdreef 2, 2300RC Leiden, The Netherlands.
e-mail: j.c.h.hardwick@lumc.nl; fax: þ31 71 524 8115.
Conflicts of interest
The authors disclose no conflicts.
Funding
J.C.H.H. is funded by the Dutch Digestive Diseases Foundation. G.J.L. is
funded by the Sloos-Alandt family.








Supplementary Table 1.Rate Ratio for Cancer Specific Mortality (Time-Dependent Analysis) for Variables other than
Statin Use
Multivariable model Reference category Rate ratio P value
Sex 1.0 (male) 0.84 (0.67–1.04) .10
Age 1.0 (continuous) 1.04 (1.03–1.06) <.001
Comorbidity 1.0 (no comorbidity) 1.39 (1.10–1.77) .007
Incidence year 1.0 (continuous) 1.02 (0.95–1.08) .60
Grade 1.0 (grade I) 1.21 (0.80–1.84) grade II <.001
2.29 (1.47–3.57) grade III
1.21 (0.70–2.08) unknown grade
Stage 1.0 (stage I) 1.53 (0.94–2.51) stage II <.001
3.80 (2.31–6.27) stage III
22.93 (13.93–37.74) stage IV
3.15 (0.42–23.89) unknown stage
Microsatellite status 1.0 (negative) 0.93 (0.63–1.37) .71
Chemotherapy 1.0 (no) 0.69 (0.52–0.90) .007
Aspirin use 1.0 (no) 0.69 (0.50–0.95) .02
Supplementary Table 2.Baseline Characteristics of the Colon Cancer Patients according to KRAS and Use of Statin After
Diagnosis. Overall statin use: 210 patients (21.0%)
All patients (N¼999)
KRAS wild-type (N¼422) KRAS mutation (N¼230)
No statin Statin P value No statin Statin P value
Sex
Male 505 (50.6) 151 (47.6) 67 (63.8) .004 95 (54.9) 39 (68.4) .073
Female 494 (49.4) 166 (52.4) 38 (36.2) 78 (45.1) 18 (31.6)
Age
<65 342 (34.2) 100 (31.6) 20 (19.1) <.001 51 (29.5) 20 (35.1) .190
66–74 304 (30.4) 82 (25.9) 53 (50.5) 47 (27.2) 20 (35.1)
75 353 (35.4) 135 (42.6) 32 (30.5) 75 (43.4) 17 (29.8)
Year of diagnosis
2002–2004 451 (45.2) 159 (50.2) 49 (46.7) .535 80 (46.2) 25 (43.9) .754
2005–2007 548 (54.8) 158 (49.8) 56 (53.3) 93 (53.8) 32 (56.1)
Disease stage
I 138 (13.8) 41 (12.9) 25 (23.8) .05 26 (15.0) 10 (17.5) .291
II 402 (40.2) 132 (41.6) 44 (41.9) 63 (36.4) 22 (38.6)
III 287 (28.7) 93 (29.3) 22 (21.0) 54 (31.2) 21 (36.8)
IV 169 (16.9) 50 (15.8) 13 (12.4) 30 (17.3) 4 (7.0)
Unknown 3 (0.3) 1 (0.3) 1 (1.0)
Comorbidity
No 443 (44.3) 153 (48.3) 16 (15.2) <.001 82 (47.4) 16 (28.1) .010
Yes 556 (55.7) 164 (51.7) 89 (84.8) 91 (52.6) 41 (71.9)
Microsatellite status
MSI 90 (9.0) 34 (10.7) 14 (13.3) .750 11 (6.4) 4 (7.0) .682
MSS 870 (87.1) 269 (84.9) 86 (81.9) 157 (90.8) 50 (87.7)
Unknown 39 (3.9) 14 (4.4) 5 (4.8) 5 (2.9) 3 (5.3)
MSI, microsatellite instable tumors; MSS, microsatellite stable tumors.
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Supplementary Table 3.Baseline Characteristics of the Colon Cancer Patients According to Intact BMP Signaling and Use of
Statin After Diagnosis
All patients (N¼999)
Non-intact BMP signaling (N¼519) Intact BMP signaling (N¼457)
No statin Statin P value No statin Statin P value
Sex
Male 505 (50.6) 195 (49.0) 73 (60.3) .029 178 (47.3) 48 (59.3) .052
Female 494 (49.4) 203 (51.0) 48 (39.7) 198 (52.7) 33 (40.7)
Age
<65 342 (34.2) 137 (34.4) 41 (33.9) .001 141 (37.5) 18 (22.2) <.001
66-74 304 (30.4) 106 (29.6) 51 (42.2) 100 (26.6) 40 (49.4)
75 353 (35.4) 155 (38.9) 29 (24.0) 135 (35.9) 23 (28.4)
Year of diagnosis
2002–2004 451 (45.2) 188 (47.2) 56 (46.3) .854 155 (41.2) 36 (44.4) .594
2005–2007 548 (54.8) 210 (52.8) 65 (53.7) 221 (58.8) 45 (55.6)
Disease stage
I 138 (13.8) 44 (11.1) 20 (16.5) .055 52 (13.8) 17 (21.0) .012
II 402 (40.2) 138 (34.7) 53 (43.8) 168 (44.7) 36 (44.4)
III 287 (28.7) 128 (32.2) 32 (26.5) 96 (25.5) 23 (28.4)
IV 169 (16.9) 86 (21.6) 16 (13.2) 60 (16.0) 4 (4.9)
Unknown 3 (0.3) 2 (0.5) 1 (1.2)
Comorbidity
No 443 (44.3) 205 (51.5) 26 (21.5) <.001 188 (50.0) 16 (19.8) <.001
Yes 556 (55.7) 193 (48.5) 95 (78.5) 188 (50.0) 65 (80.3)
Microsatellite status
MSI 90 (9.0) 34 (8.5) 10 (8.3) .425 35 (9.3) 10 (12.4) .628
MSS 870 (87.1) 356 (89.5) 106 (87.6) 333 (88.6) 70 (86.4)
Unknown 39 (3.9) 8 (2.0) 5 (4.1) 8 (2.1) 1 (1.2)
MSI, microsatellite instable tumors; MSS, microsatellite stable tumors.
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Supplementary Table 4.Time-Dependent Analysis Overall
Mortality, According to Tumor
KRAS Mutation Status, BMP
Signaling Pathway Status, and Use












1.0 (reference) 0.67 (0.51–0.87) .003
Adjusted hazard
ratio (95% CI)b,d






1.0 (reference) 0.81 (0.56–1.18) .273
Adjusted hazard
ratio (95% CI)b,d






1.0 (reference) 0.59 (0.35–1.03) .062
Adjusted hazard
ratio (95% CI)b,d






1.0 (reference) 0.46 (0.29–0.74) .001
Adjusted hazard
ratio (95% CI)b,d






1.0 (reference) 0.75 (0.53–1.06) .106
Adjusted hazard
ratio (95% CI)b,d
1.0 (reference) 0.78 (0.55–1.11) .169
aStatin use after diagnosis.
bAdjusted for sex, age, comorbidity, year of incidence,
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